Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

STRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist(R)". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID(R) (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist(R) PROGRAM.

2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).

THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA. EIGHTY PERCENT OF PATIENTS WITH DEL 5q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF PATIENTS HAD TO HAVE A SECOND DOSE DELAY/REDUCTION. GRADE 3 OR 4 HEMATOLOGIC TOXICITY WAS SEEN IN 80% OF PATIENTS ENROLLED IN THE STUDY. PATIENTS ON THERAPY FOR DEL 5q MYELODYSPLASTIC SYNDROMES SHOULD HAVE THEIR COMPLETE BLOOD COUNTS MONITORED WEEKLY FOR THE FIRST 8 WEEKS OF THERAPY AND AT LEAST MONTHLY THEREAFTER. PATIENTS MAY REQUIRE DOSE INTERRUPTION AND/OR REDUCTION. PATIENTS MAY REQUIRE USE OF BLOOD PRODUCT SUPPORT AND/OR GROWTH FACTORS. (SEE DOSAGE AND ADMINISTRATION)

3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.

This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID(R) (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID(R) (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.

You can get information abo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass Vascular ... on innovating lifesaving devices and methods for vascular ... in Series A financing, which was led by ... the deal will allow Bluegrass Vascular to obtain ... System, enhance manufacturing capabilities, and proceed with US ...
(Date:7/30/2014)... , July 30, 2014 ... CUDA programming expertise to big data, aerospace and ... eInfochips, a leading engineering R&D services company, ... develop NVIDIA GPU-powered solutions for aerospace and ... computing (HPC), industrial , and ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Dec. 5, 2011   New product launches are continually ... critical for organizations to balance the dueling goals of containing ... executives face is determining how much to invest, and how ... budget for primary care launch is spent before ...
... 5, 2011 Technology is revolutionizing healthcare — making ... lowering the cost of care. AT&T ,s* new ... — is designed to do just that. The 2011 ... awarded to AT&T for its approach to mHealth, recognizing ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 3Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 4
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... 2014 Visitors to our region recognize ... to ensure its protection. Bob Kiesendahl, one of the ... the Delaware Highlands Conservancy for donations collected through participation ... donations add up fast, as visitors welcome the opportunity ... River Region. , The Kiesendahl family has owned Woodloch ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... DRE Medical — a leading medical ... of its Medical Trade Shows & Conventions Calendar ... and equipment vendors. , The calendar is a continually-updating ... United States and around the world. Hundreds of entries ... is always growing. , Information listed on each trade ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... School of Engineering and Applied Science have taken a ... successfully using the bacterium Escherichia coli to ... polyketides, which include important antibiotic and anticancer drugs. ... potent chemical compounds produced by living organisms; many are ...
... 2008 The Women,s Heart Health Initiative at the ... a new fellowship dedicated to gender-specific research that will ... in women. The announcement will take place during a ... "Women face unique challenges to successful diagnosis and treatment ...
... offered the perfect job. The not-so-good news it,s ... people with diseases like HIV, or those who are simply ... a medical exam to qualify for a job can be ... brings excellent news. , Medical exams are often not an ...
... Women with deficiency at time of delivery had almost ... 22 (HealthDay News) -- Vitamin D deficiency greatly increases ... U.S. researchers report. , During the two-year study, Boston ... examined the relationship between vitamin D levels in pregnant ...
... oncology researcher Dr. Daniel Von Hoff, a member ... an in-depth look at the "lost opportunity" in ... biotechnology companies use the phase I trial to ... Hoff advocates that it can also provide valuable ...
... from overweight and obesity. This is the result of a ... Elisabeth Weber and her coauthors present the results in the ... Arztbl Int 2008; 105 [51-52]: 883-9). The doctors recorded ... children, but also their mother tongue. Their parents had to ...
Cached Medicine News:Health News:E. coli engineered to produce important class of antibiotic, anti-cancer drugs 2Health News:A simple questionnaire to replace a doctor's exam 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 3Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 4
... a plastic device that fits over a standard ... a minimum amount of reagent. , , ... between the coverplate and slide. The liquid ... is dispensed into the well. Its pressure ...
ISI Micro Brushes are available in a variety of French diameters. Made with stainless steel handles and nylon bristles, the ISI Micro Brushes will last through countless cleanings....
... ISI offers instrument cleaning brushes ... diameters and composition. The long, ... cannulas and tubing. The smallest ... micros. The brass and stainless ...
... Nest is the wall organizer with a complete ... of sizes and diameters. Made of tough, durable ... Brush Nest is the ultimate organizer. , The ... in a variety of lengths, diameters and composition.,The ...
Medicine Products: